Halil Taskaynatan*, Ummu Sena Sarı**, Yasar Yildiz*, Tarik Salman*, Utku Oflazoglu*, Umut Varol*, Ozlem Ozdemir*, Ahmet Alacacioglu*, Tuna Demirdal**, Fatih Esat Topal***, Mustafa Oktay Tarhan****, Yuksel Kucukzeybek*
*Department of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey - **Department of Infectious Diseases, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey - ***Department of Emergency Medicine, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey - ****Institute of Oncology, Dokuz Eylul University, Izmir, Turkey
known. The prognosis of patients with extreme leukocytosis mainly depends on the underlying disease.
Materials and methods: In the present study, the data of patients with pathologically confirmed non-hematologic malignant tumor who had a leukocyte count >30,000/µL within the period between 2006 and 2018 were retrospectively evaluated.
Results: A total of 111 patients with a leukocyte count >30,000/µL were included in the study. Eighteen of the patients had been diagnosed with paraneoplastic leukemoid reaction (PLR) while 19 patients had infection-associated leukocytosis (IAL). While there was no significant difference between the PLR and IAL groups in terms of sex (p=0.254), histological type of tumor (p=0.313) and liver metastasis (p=0.147), lung metastasis was more common (p=0.033) in the PLR group. The median overall survival was 17 weeks (95% confidence interval [CI], 4.5 to 29.5) in patients with PLR while it was 25 weeks (95% CI, 16.5 to 33.5) in patients diagnosed with infection (p=0.041).
Conclusion: Extreme leukocytosis was found to have multiple etiologies including hematopoie-tic growth factor use, infections, high-dose corticosteroid use, new
Non-hematologic cancer, leukocytosis, paraneoplastic leukemoid reaction, prognosis.